miRNA icroRNAs – developing new tools for diagnostics · 2009. 4. 30. · miRNA icroRNAs –...
Transcript of miRNA icroRNAs – developing new tools for diagnostics · 2009. 4. 30. · miRNA icroRNAs –...
i RNA microRNAs – developing new tools for diagnostics –
Join forces with IMGM Laboratories to make your miRNA project a success
D C l WDr. Carola WagnerIMGM Laboratories GmbH
Martinsried, Germany
qPCR 2009 SymposiumMarch 10th, 2009
Agenda
• IMGM - your outsourcing partner (in brief)
• Our service portfolio (in brief)
• miRNA in diagnostics
• workflow: microarray-based miRNA profiling
• Summary
10.03.2009 © IMGM Laboratories 2009 Slide 2
IMGM Laboratories your outsourcing partnerIMGM Laboratories – your outsourcing partner
10.03.2009 © IMGM Laboratories 2009 Slide 3
IMGM – your outsourcing partner some basic factssome basic facts
IMGM L b i f d d i 2001• IMGM Laboratories was founded in 2001
• We are located on the biotech campus pMartinsried / Munich
W t i id ff i • We operate as service provider offering advanced genomic services
• Our customers come from academia, pharma and biotech
• a flexible and reliable partnership(e.g. small and dedicated team)
10.03.2009 © IMGM Laboratories 2009 Slide 4
IMGM – your outsourcing partner some basic factssome basic facts
• strategic partnership with the “Center for human genetics and laboratory strategic partnership with the Center for human genetics and laboratory medicine Dr. Klein & Dr. Rost”
• full accreditation according to DIN EN ISO/IEC 17025
f ll d f l b d h l • full accreditation for expression analysis based on whole genome microarrays and quantitative real-time PCR
• Agilent Certified Service Provider
10.03.2009 © IMGM Laboratories 2009 Slide 5
IMGM Laboratories Service PortfolioIMGM Laboratories – Service Portfolio
10.03.2009 © IMGM Laboratories 2009 Slide 6
Service Portfolio
10.03.2009 © IMGM Laboratories 2009 Slide 7
Service PortfolioRNA servicesRNA services
RNA services:RNA services:• Microarrays (Agilent platform, multiple options)• Real-Time PCR (AB 7900HT, TaqMan arrays,
96 and 384 well blocks gene expression studies)96- and 384-well blocks, gene expression studies)
• microRNA profiling• RNA isolation
RNA l l • RNA quality control (Agilent Bioanalyzer | Nanodrop)
10.03.2009 © IMGM Laboratories 2009 Slide 8
microRNAs and their potential in diagnostics
10.03.2009 © IMGM Laboratories 2009 Slide 9
miRNAs in diagnostics
miRNAs / miRNA profiles:miRNAs / miRNA profiles:
• association to ~70 diseases association to 70 diseases (HMDD, human microRNA disease database, last update 2008-10-17)
• active players in human oncogenesise.g. miR-21 onco-miRNA for breast cancer (Qian et al. (2008) Breast Cancer Res Treat; c f Sassen et al (2008) Virchows Arch 452:1-10Treat; c.f. Sassen et al. (2008) Virchows Arch 452:1 10
• classify human cancerse.g. Lu et al. (2005) Nature 435:834-838Volinia et al. (2006) Proc Natl Acad Sci USA 103:2257-2261
10.03.2009 © IMGM Laboratories 2009 Slide 10
miRNAs in diagnostics
miRNAs / miRNA profiles associated with:
• disease prognosis:− miR-221/222 cluster associated with poor prognostic in thyroid
ill i ti d i & li bl tpapillary carcinomas, pancreatic adenocarcinoma & glioblastoma(Lesage et al. (2007) Cell Cycle 6)
− Low let-7(a) expression associated with shorter survival and poor i f l ti t prognosis for lung cancer patients
(Takamizawa et al. (2004)Cancer Res 64:3753-3756; Yanaihara et al. (2006) Cancer Cell 9:189-198)
• prognosis of therapy outcome and response− high expression of miR-21 associated with poor survival and poor
h f l dtherapeutic outcome of colon adenocarcinoma(Schetter et al. (2008) JAMA 299(4):425-436)
− prediction of chemotherapeutic response in patients with breast cancer according to miRNA signature(Salter et al. 2008) PLoSOne 3(4):e1908)
10.03.2009 © IMGM Laboratories 2009 Slide 11
miRNAs in diagnostics
Actual examples of miRNA diagnostic tests:Actual examples of miRNA diagnostic tests:
• Chronic pancreatitis vs. pancreatic cancer (Asuragen)
• Prediction of colon cancer (launch early 2009, Exiqon A/S)
• Differentiation of mesothelioma from other cancers (miRview meso, Rosetta Genomics)
• Identification of squamous-type lung cancers (miRview squam Rosetta Genomics)(miRview squam, Rosetta Genomics)
• Identification of tissue-of-origin of metastatic tumors ( )(miRview mets, Rosetta Genomics)
10.03.2009 © IMGM Laboratories 2009 Slide 12
Possibilities for you to join
the field of miRNA research !!!the field of miRNA research !!!
10.03.2009 © IMGM Laboratories 2009 Slide 13
miRNA profiling the general workflowthe general workflow
IMGM /Customer Agilent Bioanalyzer Catalog/Custom ArraysSample Size IMGM /Customer Agilent Bioanalyzer Catalog/Custom ArraysSample Size
Project Consulting
Sample Preparation
Quality Control
Agilent DNA Microarrays
BioinformaticData Analysis
Hit Validationwith qPCR
miRNA mimicor inhibition
Functionalanalysis
Deregulated GenesAB7900HT/TLDAsCustomere.g. mRNA microarrays
10.03.2009 © IMGM Laboratories 2009 Slide 14
(GEx)
miRNA profilingsample preparationsample preparation
Sample types:• Cells
Ti• Tissues• Blood and PBMCs• FFPE
e.g. Li et al. (2007) BMC Biotechnology 7:36Xi et al. (2007) RNA 13:1668-1674Siebolts et al. (2009) J Clinc Path 62(1):84-88
• Body fluids e g serum urine salvia amniotic fluid pleural fluide.g. serum, urine, salvia, amniotic fluid, pleural fluide.g. Chen et al. (2008) Cell Research 18:997-1006Gilad et al. (2008) PLoS One 3 (9):3148Hunter et al (2008) PLoS One 3 (11):e3694
10.03.2009 © IMGM Laboratories 2009 Slide 15
Hunter et al. (2008) PLoS One 3 (11):e3694
miRNA profiling(mi)RNA quality control & quantification(mi)RNA quality control & quantification
10.03.2009 © IMGM Laboratories 2009 Slide 16
www.agilent.com/chem/labonchip
10.03.2009 © IMGM Laboratories 2009 Slide 17
Tissot (2008) Agilent Application Note, Publication Number 5989-7878EN; www.agilent.com/chem/laponchip
miRNA profilinge g Agilent Microarray Workflowe.g. Agilent Microarray Workflow
Total RNA incl. small RNAs(100 )(100ng)
direct RNA 3’end Labelingwith Cy3-pCp
Labeled RNAs
hybridization on microarrays
miRNA profile
10.03.2009 © IMGM Laboratories 2009 Slide 18
miRNA profiling Data analysisData analysis
10.03.2009 © IMGM Laboratories 2009 Slide 19
Technical Note 15 (3), www.ambion.com Yanaihara et al. (2006) Cancer Cell 9(3):189-198
miRNA profiling Data analysisData analysis
Sample treated log2 data
Collaborative work with SIRION BIOTECH:Thirion et al. (2009) qPCR 2009 – RNAi:
microRNA – siRNA applications
S l d
10.03.2009 © IMGM Laboratories 2009 Slide 20
Sample_untreated log2 data
miRNA profiling Hit validation by qPCRHit validation by qPCR
6
* ** * **linear Fold
2
4
Fold Change
2
‐2
0
calibrator miR‐103
calibrator miR‐27a
calibrator miR‐23b + miR_103
-2
‐6
‐4 Collaborative work with SIRION BIOTECH:Thirion et al. (2009) qPCR 2009 – RNAi:
microRNA siRNA applications
‐8
6
* p<0.05
microRNA – siRNA applications
10.03.2009 © IMGM Laboratories 2009 Slide 21
‐10p
** p<0.01
miRNA profiling e g functional analysis by mRNA expression profilinge.g. functional analysis by mRNA expression profiling
miRNA overexpression miRNA
inhibition inhibition mRNA profiling
= gene expression
analysis
10.03.2009 © IMGM Laboratories 2009 Slide 22
www.thco.com.tw
Summary
Single miRNAs / miRNA profiles in relation to diagnostics:• Well established miRNA technologies• Increased number of publications with promising results
Fi t di ti t t l h d • First diagnostic tests launched
miRNA research for you powered by IMGM laboratories:miRNA research for you powered by IMGM laboratories:• Advanced genomic services with one focus on RNA services and miRNA
services• State-of-the-art technology to provide top-quality data• Full accreditation – especially for microarray- and qPCR-based expression
analysisanalysis• Sound bioinformatics to extract meaningful results• Expert knowledge in molecular genetics and medical diagnostics
10.03.2009 © IMGM Laboratories 2009 Slide 23
Thank you very much for your attention!
We are open for business…
The IMGM Laboratories TeamD. Wiegand, M. Hirt, S. Brauer, S. Kotschote, H-G. Klein, R. Oehlmann, C. Wagner, M. Sohns
www.imgm.com
10.03.2009 © IMGM Laboratories 2009 Slide 24